Chemotherapy is widely used to treat cancers with the intent to cure or prevent recurrence. There are several medications used to treat or manage cancer and tumor growth. Healthcare providers (HCPs) should be familiar with these medications. This also includes their indication, mechanism of action (MOA), dosing regimen, and adverse effects.
The goal of this course is to assist registered nurses, advanced practice registered nurses, physicians, pharmacists, and physician’s assistants with up-to-date information on the commonly used drug classes of chemotherapy agents.
Chemotherapy is widely used to treat cancers with the intent to cure or prevent recurrence. There are several medications used to treat or manage cancer and tumor growth. Healthcare providers (HCPs) should be familiar with these medications. This also includes their indication, mechanism of action (MOA), dosing regimen, and adverse effects. The goal of this course is to assist registered nurses, advanced practice registered nurses, physicians, pharmacists, and physician’s assistants with up-to-date information on the commonly used drug classes of chemotherapy agents.
In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
In support of improving patient care, Relias LLC is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Arkansas State Board Of Nursing Approved Continuing Education program (CEBroker Provider #50-290).
Bahamas Medical Council (CEBroker Provider #50-290)
Physicians will receive 1.00 AMA PRA category 1 Credits™.
District of Columbia Board of Nursing Approved Continuing Education program (CEBroker Provider #50-290).
Florida Board of Medicine (CEBroker Provider #50-290)
Physicians will receive 1.00 AMA PRA category 1 Credits™.
Florida Board of Nursing (CEBroker Provider #50-290)
Florida Board of Pharmacy (CEBroker Provider #50-290)
Florida Physician Assistants (CEBroker Provider #50-290)
Georgia Board of Nursing (CEBroker Provider #50-290)
Georgia Composite Medical Board - Physician Assistants (CEBroker Provider #50-290)
Kansas State Board of Nursing (CEBroker Provider #50-290)
Kentucky Board of Nursing (CEBroker Provider #50-290)
Nurses will receive 1.00 contact hours for participating in this course.
Louisiana State Board of Medical Examiners (CEBroker Provider #: 50-290)
Physicians will receive 1.00 AMA PRA category 1 Credits™.
Michigan Board of Nursing (CEBroker Provider #50-290)
Michigan Board of Pharmacy (CEBroker Provider #50-290)
Mississippi Board of Nursing (CEBroker Provider #50-290)
Mississippi State Board of Medical Licensure (CEBroker Provider #: 50-290)
New Hampshire Medical Society (CEBroker Provider #50-290)
Physicians will receive 1.00 AMA PRA category 1 Credits™.
New Mexico Board of Nursing (CEBroker Provider #50-290)
Physicians will receive 1.00 AMA PRA category 1 Credits™.
North Dakota Board of Nursing (CEBroker Provider #50-290)
State Medical Board of Ohio (CEBroker Provider #: 50-290)
South Carolina Board of Medical Examiners (CEBroker Provider #50-290)
South Carolina Board of Nursing (CEBroker Provider #50-290)
Tennessee Board of Medical Examiners (CEBroker Provider #50-290)>
Physicians will receive 1.00 AMA PRA category 1 Credits™
West Virginia Board of Registered Nursing (CEBroker Provider #50-290)
Wyoming Board of Nursing (CEBroker Provider #50-290)
Outline:
Section 1: Introduction
About This Course
Learning Objectives
Section 2: Introduction to Chemotherapy
The Purpose of Chemotherapy
Therapeutic Uses
Delivery Methods
Dosing
Section 3: Anticancer Drugs
MOA Overview
Adverse Effects
Section 4: Cell Cycle Specific (CCS) Antineoplastic Agents
Anti-Metabolites
Topoisomerase Inhibitors
Mitosis Inhibitors
Section 5: Cell-Cycle Non-Specific (CCNS) Antineoplastic Agents
Anti-Tumor Antibiotics
Alkylating Agents
Platinum Analogs
Section 6: Other Chemotherapy Agents
Targeted Therapy
Kinase Inhibitors
Immune Checkpoint Inhibitors
Miscellaneous Anticancer Drugs
Section 7: Clinical Vignette
Non-Hodgkin’s Lymphoma
Section 8: Conclusion
Course Summary
Course Contributors
Resources
References
Alia Lutz, BA, BSN, RN, has over 10 years of experience as a Registered Nurse with a focus on cardiothoracic, respiratory, and coronary care. She has also had experience in Med-Surg, step-down and ICU. Prior to joining Relias as a SME and Content Writer for acute care, she provided virtual education and injection training on injectable biologics to patients, reported adverse events, and was a patient advocate. She has collaborated with peers on creating job aids, writing policies, and improving quality of care and documentation. Alia received her Bachelors in Nursing from Otago Polytechnic in New Zealand in 2011.Subject Matter Expert: Johnny J. Bethea, II, RPh
Johnny received a B.S. Pharmacy degree from the College of Pharmacy at the Medical University of South Carolina. He has earned certificates in Medication Therapy Management, Injectable Medications, and Asthma Therapy Management. At Relias, Johnny serves as a Partner in Behavioral Health Solutions, where duties include serving on Clinical Analytics and Applications Team, developing algorithms to improve clinical outcomes, engineering clinical consultant, SME, writer, and editor. In addition, he has served on the Executive Board of Directors for CMHCs and other medical organizations, pharmacy manager, APPE Preceptor, and college of pharmacy dean’s advisory council.
Access to over 1,450 courses! Access to 1,450+ courses for one low price.